ORIGINAL RESEARCH article

Front. Immunol.

Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1568683

This article is part of the Research TopicAdvances in Understanding and Managing Systemic Sclerosis-Associated Interstitial Lung Disease: Bridging Prognostic Biomarkers to Therapeutic InnovationsView all articles

Identifying inflammatory phenotypes associated with lung involvement in systemic sclerosis: k-means clustering approach AUTHORS

Provisionally accepted
Laura  Cano-GarcíaLaura Cano-García1Aimara  García-StuderAimara García-Studer1Sara  Manrique-ArijaSara Manrique-Arija2*Fernando  Ortíz-MarquezFernando Ortíz-Marquez1Rocío  Redondo-RodríguezRocío Redondo-Rodríguez1Paula  Borregón-GarridoPaula Borregón-Garrido1Natalia  Mena-VázquezNatalia Mena-Vázquez1Antonio  Fernandez-NebroAntonio Fernandez-Nebro3
  • 1Instituto de Investigacion Biomédica de Málaga IBIMA-BIONAND. UGC de Reumatología, HRU de Málaga., Málaga, Spain
  • 2UGC de Reumatología, HRU de Málaga, Departamento de Medicina y Dermatologia ., Biomedical Research Institute of Malaga, University of Malaga, Málaga, Spain
  • 3Departaento de Medicina y Dermatología, Instituto de Investigacion Biomédica de Málaga IBIMA-BIONAND. UGC de Reumatología, HRU de Málaga., Málaga, Andalusia, Spain

The final, formatted version of the article will be published soon.

Objective: to assess the prognostic impact of clusters of hematologic and biochemical indices on interstitial lung disease (ILD) and respiratory damage associated with systemic sclerosis (SSc) Methods: Design: We conducted a cross-sectional, uncontrolled study. Participants and Settings: a cohort of patients with SSc (2013 ACR/EULAR criteria) were enrolled in the rheumatology unit of a tertiary hospital in southern Spain. Primary and secondary outcome measures: The primary outcomes were the presence of SSc-ILD and respiratory damage, assessed via the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI). Inflammatory biomarkers, including both CRP and hematological indices, were obtained. Patients were grouped based on inflammatory phenotypes derived from longitudinal CRP averages and through principal component analysis (PCA) with K-means clustering of cross-sectional variables. Multivariate models were constructed to identify factors associated with SSc-ILD and respiratory damage.Results: Among 83 patients with SSc, 33.7% had ILD, 30.1% had respiratory damage, and 28.9% were receiving immunosuppressive therapy. A persistent inflammatory phenotype during follow-up was associated with non-Caucasian ethnicity (OR 14.0) and SSc-ILD (OR 17.9). Cross-sectional inflammatory clusters were linked to SSc-ILD (OR 12.8) and damage measured by SCTC-DI (OR 1.2). PC-2, derived from CRP-based variables, was a better predictor of SSc-ILD (OR 3.0) than PC-1, which was based on hematological indices (OR 0.5, non-significant), especially in the presence of anti-Scl70+ antibodies (OR 19.1) and immunosuppressants (OR 42.2). The only variables associated with respiratory damage were average CRP during follow-up (OR 1.2), anti-Scl70+ (OR 7.7), and glucocorticoids (OR 0.2). Conclusion: CRP-based variables seem to be better predictors of SSc-ILD and respiratory damage than hematological indices.

Keywords: systemic sclerosis, Interstitial Lung Disease, Inflammation, C-Reactive Protein, Hematological indices, Inflammatory biomarkers, principal component analysis (PCA), inflammatory phenotypes

Received: 30 Jan 2025; Accepted: 09 Apr 2025.

Copyright: © 2025 Cano-García, García-Studer, Manrique-Arija, Ortíz-Marquez, Redondo-Rodríguez, Borregón-Garrido, Mena-Vázquez and Fernandez-Nebro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Sara Manrique-Arija, UGC de Reumatología, HRU de Málaga, Departamento de Medicina y Dermatologia ., Biomedical Research Institute of Malaga, University of Malaga, Málaga, Spain

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Research integrity at Frontiers

94% of researchers rate our articles as excellent or good

Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


Find out more